#EULAR2023 #POS1207 Promising therapy for dermatomyositis. Data from Stage One of Phase 2 RCT (N=18) showed Anti-IFN Beta mAb improved clinical, PROs, extra-muscular activity and reduced CK levels vs Placebo. No cases of HZV. One to watch out in the next few years @RheumNow https://t.co/Oh8sZlMzUt

Factors related to having a flare of arthritis during COVID-19 include female gender, higher disease activity, no DMARD at time of vaccination. Stopping DMARDs need to be weighed up against risk of flares, Pedro Machado, COVID-19 #EULAR2023 @RheumNow https://t.co/3sd32tF2kW

The modern day poster tour #EULAR2023: the posters & speakers come to you, broadcast through a headset (it’s almost like a silent disco, in a hall with lots of background noise). Definite innovation but at capacity, wish more people could tune in on their own devices @RheumNow https://t.co/sOXnYctsfN

Debate @ #EULAR2023 ⁦@eular_org⁩ about clinically suspect arthralgia. Myth or just #rheumatoid #arthritis in the making? https://t.co/Kj4CeE3NtU

Did you know? Painter Peter Paul Rubens had Rheumatoid Arthritis as demonstrated in swellings and deformities observed in this self-portrait An image I often use in my teaching to student of clinical aspects of RA #rheumatologyandart #teachingpearls #EULAR23 @RheumNow https://t.co/xwDisTUHdy

#EULAR2023 #POS1124 My newly diagnosed patients & their carers often expressed heightened anxiety with poor quality web info about #SLE. Thank you @LupusEurope for this wonderful effort 👏. Available in most European languages too @RheumNow https://t.co/cr5Ls117xM

Study on folylPG synthétase (FPGS) activity and MTX-PG measured in sperm showed low bio active form of MTX-PG, low FPGS activity resulting in lower capacity to form MTX-PG, Perez-Garcia LF, Abst#OP0224 #EULAR2023 @RheumNow https://t.co/8sGQOBxn8r

A shame. Pts with #scleroderma are dying waiting for organ transplant- we should list and work them up for Tx earlier. PAH Pts May do worse @eular_org #EULAR2023 @RheumNow OP0241 https://t.co/8ZlHJmETGA

Herpes Zoster vaccination in RA patients treated with Upadacitinib and MTX showed a satisfactory response, slight reduction in response compared to general population in both antibody and cell mediated responses Winthrop K, Abst#OP0225 #EULAR2023 @RheumNow https://t.co/wxwbOYsn5K

#EULAR2023 #POS0222 Post-hoc Analyses of Phase 3 RCT in Rituximab-treated ANCA vasculitis patients only (65% of total) showed more patients met Remission rate & with lower GC Toxicity vs Pred Taper + RTX at 52 weeks, consistent with Trial Main Results @RheumNow https://t.co/BmiujbhQI9

Let le introduce you to ARTHUR 🤖 A very skilled robot who scans your hands and wrists in 15 mn 🤚 Amazing to see new #AI developments that will make our lifes’ easier! #EULAR23 @ROPCA3 @JustSoren Stand M6 @RheumNow https://t.co/7PtR2CGqTt

So what kind of changes do we see in ACPA+ arthralgia patients, in the 6 months prior to them developing inflamm arthritis? - ACPA titre up, RF pos - EMS, pain up - ESR up Good things to keep an eye on in pre-RA Emery group POS1046 #EULAR2023 @RheumNow https://t.co/cSKPb5SbVH

‘Where have all the rheumatoid nodules gone?’ (Fantastic poster title @MayoClinic) Don’t get to see them much in clinic anymore. Almost surprised when I do Smoking is down Therapies are better RA is changing (a fact worth remembering!) POS1066 #EULAR2023 @RheumNow https://t.co/VxDNusIjOa

#EULAR2023 #POS1069 SLR & meta-analysis to inform EULAR Points to Consider which included 15 studies showed that targeted therapies were not associated with increased risk of cancer recurrence in patients with inflammatory arthritis AND a historyof cancer (85% had RA) @RheumNow https://t.co/uK2XHLjpj8

‘Clinically suspect arthralgias: fact or myth’ - a great debate topic #EULAR2023 First, the argument for. And we start with a reminder as to what we really mean by CSA @RheumNow https://t.co/e1CdxKi69m